Position
Third Point in ARS Pharmaceuticals, Inc.
Back to the book · All holders of SPRY
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$20K$8.03 → $8.01
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 556.2K | $6.48M | — | — | — | 0.1% |
| Q1 2026 | 1M | $8.03M | $8.03 | −$2.01M | $3.56M | 0.4% |
| Q2 2026 | 1M | $8.01M | $8.01 | −$20K | −$0 | 0.2% |